C oronary artery bypass grafting (CABG) has been shown to prolong the life expectancy of several subgroups of patients with coronary artery disease, [1] [2] [3] including those with left ventricular dysfunction. 4, 5 However, because surgical revascularization in these patients is associated with an increased risk of perioperative mortality, 6 ,7 the long-term survival benefit of CABG surgery is dependent on low operative mortality rates. Risk factors for operative mortality after CABG have been defined by several investigators 8 -13 and include urgency of operation, left ventricular ejection fraction (LVEF), reoperation, age, sex, and presence of left main coronary artery disease. However, only a few studies have focused on clinical predictors of operative mortality after CABG in patients with left ventricular dysfunction and have reported inconsistent results. In one study of 466 patients with LVEF Ͻ0.40, 7 operative mortality was related to ejection fraction, being increased in patients with lower LVEF. In contrast, in an analysis of 224 patients with LVEF Ͻ0.30, 14 mortality was not influenced by decreasing ejection fraction but instead by clinical markers of heart failure, such as New York Heart Association (NYHA) class and left ventricular end-diastolic pressure (LVEDP). Finally, another study 15 identified age and renal dysfunction as predictors of operative mortality but did not note an increased mortality in patients with heart failure.
The CABG Patch Trial 16 was a prospective, randomized trial designed to test the hypothesis that prophylactic insertion of an implantable cardioverter-defibrillator (ICD) would reduce mortality rates in CABG patients predicted to be at high risk for late arrhythmic death. Results of that trial have been previously reported. [17] [18] [19] The purpose of the present study was to use the CABG Patch Trial database to identify predictors of perioperative mortality in a large group of CABG patients with preoperative left ventricular dysfunction.
Methods

Study Patients
Randomization and data collection in the full-scale CABG Patch Trial were conducted between March 12, 1993, and February 5, 1996 , at 37 centers in the United States and Europe. Informed consent was solicited from each enrolled patient. Inclusion criteria were a clinical indication for elective CABG, age Ͻ80 years, LVEF Ͻ0.36, and an abnormal signal-averaged ECG. The last criterion was selected to reduce the number of patients with a low risk of arrhythmic events after CABG surgery. 20 Exclusionary criteria included emergency CABG, history of sustained ventricular tachycardia, ventricular fibrillation or cardiac arrest with inducible ventricular tachycardia, previous or concomitant mitral or aortic valve surgery, or concomitant surgery for arrhythmia or ventricular aneurysm. A complete list of proposed and actual reasons for exclusion from the trial has been published previously. 21 If the surgeon agreed intraoperatively that randomization was appropriate, patients were randomized to undergo routine conclusion of surgery or ICD insertion with epicardial rate-sensing electrodes and patch leads. Patients were followed at 3-month intervals for 42 months, corresponding to the anticipated useful battery life of the ICDs. During the recruitment period, 71 855 patients were screened, 1422 eligible patients were identified, 1055 were enrolled and signed consent forms, and 900 were randomized. Details of the randomization procedure have been described previously. 16, 21 
Statistical Analysis
Severity of clinical heart failure and of angina pectoris was graded by the NYHA and Canadian Cardiovascular Society (CCS) classifications, respectively. For the present analysis, randomized patients were classified into 3 subgroups according to severity of angina: those without symptoms of angina for the past 3 months, those with CCS class I/II symptoms of angina, and those with CCS class III/IV symptoms of angina. Patients were also classified into subgroups according to severity of heart failure symptoms: those without symptoms, those with NYHA class I/II symptoms, and those with NYHA class III/IV symptoms.
Perioperative mortality and hospital length of stay were analyzed for patients in each heart failure and angina symptom grouping. Perioperative mortality was defined in the present study by death within 30 days of CABG or within 90 days of CABG in continually hospitalized patients. Length of stay was defined by the number of days from the date of coronary bypass surgery to hospital discharge. Fisher's exact test or Mantel-Haenszel 2 tests were used for mortality data, and 2-sided unpaired t tests were applied to lengthof-stay data.
Single-variable tests of significance were performed on perioperative mortality and postoperative length-of-stay data by use of a set of candidate variables selected by literature review, including angina and heart failure symptom group, age, sex, LVEF, LVEDP, and history of chronic obstructive pulmonary disease (COPD), hypertension, diabetes, and stroke. Logistic and linear regression models were used to analyze perioperative mortality and length of stay, respectively. Next, stepwise multiple regression analyses were performed with the use of those variables that were statistically significant in the single-variable analyses. All statistical tests were performed to reject the null hypothesis at a level of ␣ϭ0.05. To prevent confounding due to shortened lengths of stay for the patients who died perioperatively, patients in this group were not included in linear regression models of length of stay. Data are expressed as number of patients. Numbers in parentheses indicate the percentage of patients from the total patient population for the specified condition. Values in parentheses indicate number of patients in each group. Data were missing for 60 patients. There were 47 perioperative deaths among the 840 remaining patients.
TABLE 3. Perioperative Mortality Rates by Heart Failure and Angina Symptoms
Results
Patient Demographics and Preoperative Characteristics
A summary of the demographic profile and preoperative medication regimens of the 900 randomized patients is shown in Table 1 . Data regarding congestive heart failure (CHF) class were missing for 3 patients, and data regarding angina class were missing for 57 patients, yielding 840 patients with complete symptom data. Mean age was 63.5 years, and the majority of patients were male, smoked cigarettes, or had a history of Ն1 myocardial infarction. Significant proportions of the study cohort were hypertensive, hypercholesterolemic, or diabetic, and almost 11% had had previous coronary artery bypass surgery. All patients had low preoperative ejection fraction (Ͻ0.36), and 16% had severely depressed ventricular function (LVEF Ͻ0.20). Fifty percent of patients had clinical heart failure, whereas 75% had angina pectoris. Table 2 lists the breakdown of patients according to CHF and angina class.
Perioperative Mortality
Overall perioperative mortality was 5.6% in the 840 randomized patients for whom complete data on symptoms were available (Table 3 ). Perioperative mortality rates were 3.3% among patients without heart failure, 8.2% among patients with class I/II heart failure, and 7.7% among patients with class III/IV heart failure. Perioperative mortality rates were 4.3% among patients without angina, 5.9% among patients with class I/II angina, and 6.1% among patients with class III/IV angina. In single-variable analyses (Table 4) , there was a statistically significant association between perioperative mortality and heart failure symptom group (Pϭ0.018) but not between perioperative mortality and angina symptom group (Pϭ0.932). The only other variable that was significantly associated with perioperative mortality in the single-variable analyses was reoperation, ie, a history of CABG before the index surgery. In stepwise multiple logistic regression analyses with the log odds of perioperative mortality as the dependent variable, class I/II and class III/IV heart failure symptoms were each associated with a 2.4-fold increase in the odds of perioperative mortality compared with absence of Data were missing for the following comparisons: heart failure (nϭ897), angina (nϭ843), reoperation (nϭ899), COPD (nϭ895), smoking (nϭ899), LVEDP (nϭ716), and left main disease (nϭ833). Data were analyzed by univariate logistic regression (see Methods).
heart failure ( Table 5) . Compared with primary CABG, reoperation was associated with a 3.8-fold increase in the odds of perioperative mortality.
Hospital Length of Stay
Among the randomized patients for whom complete data on symptoms were available, average length of stay was 10.3Ϯ10.0 (median, 8) days (Table 6 ). Unadjusted lengths of stay were 9.2Ϯ6.9 (median, 7) days among patients without heart failure, 11.9Ϯ14.8 (median, 8) days among patients with class I/II heart failure symptoms, and 10.9Ϯ9.5 (median, 8) days among patients with class III/IV heart failure symptoms. Unadjusted lengths of stay were 10.2Ϯ10.1 (median, 8) days among patients without angina, 10.3Ϯ10.3 (median, 7) days among patients with class I/II angina symptoms, and 10.3Ϯ9.8 (median, 8) days among patients with class III/IV angina symptoms. In single-variable analyses (Table 7) , there was a statistically significant association between length of stay and heart failure symptom group (Pϭ0.008) but not between length of stay and angina symptom group (Pϭ0.247). Age in decades, history of stroke, defibrillator group status, and LVEF were also significantly associated with length of stay in single-variable analyses. In stepwise multiple linear regression analyses with length of stay as the dependent variable, class I/II heart failure symptoms were associated with 2.3 additional days in the hospital compared with absence of heart failure (Pϭ0.006), and class III/IV symptoms were associated with 1.4 additional days in the hospital (Pϭ0.08). Age, history of stroke, and defibrillator group status remained statistically significant in multiple regression analyses (Table 8) .
Discussion
Since the advent of CABG for the treatment of ischemic heart disease, several investigators have attempted to define preoperative characteristics predictive of postoperative success and survival. In an early report, Kennedy et al 10 performed discriminant analyses of data from the Coronary Artery Surgery Study (CASS) to determine those variables that would predict operative mortality. In 6176 patients who underwent isolated CABG from 1975 through 1978, overall operative mortality was 2.3% and was increased by age, high-grade left main coronary artery occlusion, female sex, poor left ventricular wall motion, increased LVEDP, and the presence of pulmonary rales on physical examination. Myers et al 11 performed a further analysis of 8991 patients in the CASS study who underwent isolated CABG from 1974 through 1979 and identified CCS angina classification and CHF score as additional determinants of mortality. Notably, the CASS study excluded patients with LVEF Ͻ0.35. More recently, Christakis et al 9 studied 7334 patients who underwent isolated CABG at 3 teaching hospitals from 1982 to 1986. Overall operative mortality for CABG was 3.7% and was significantly higher with emergency surgery, depressed LVEF, increasing age, and previous CABG surgery. In a study investigating the influence of clinical heart failure on operative mortality, Wechsler and Junod 13 examined nearly 6000 patients who underwent CABG at 2 centers. In one center, operative mortality was 0.75% in patients without CHF and 6.8% in patients with class IV CHF; in the other, mortality was 3.0% without CHF and 14.9% with class IV CHF. Additionally, these authors found that patients with class IV angina fared worse than did those with milder degrees of angina.
In contrast to the above reports, which represent only a small fraction of the published literature on risk factors for mortality after CABG, relatively few studies have focused on patients selected on the basis of ventricular dysfunction. Before the present analysis, the largest group of patients with ventricular dysfunction to be studied was reported by Hochberg et al. 7 In this 1983 analysis of data from 466 patients with ejection fractions Ͻ0.40, overall operative Values in parentheses indicate number of patients in each group (not including patients who died perioperatively). Data for 57 patients were missing. mortality after CABG increased progressively as ejection fraction decreased, from 11% in patients with ejection fractions between 0.20 and 0.39 to 37% in patients with ejection fractions Ͻ0.20. A decade later, Hausmann et al 14 reported a prospective study of 224 patients with ejection fractions of 0.10 to 0.30 who underwent CABG. Overall operative mortality was 8.9%, and in single-variable analyses, LVEDP Ͼ24 mm Hg, number of prior myocardial infarctions, and class III or IV heart failure were significantly associated with operative mortality. In that analysis, symptoms of angina and LVEF were not correlated with mortality. Subsequently, Kaul et al 15 reported a study of 210 patients with ejection fractions of Յ0.20 who underwent CABG, with an operative mortality of 10%. Early mortality was significantly correlated with age but was not influenced by preoperative heart failure, previous CABG, or the sex of the patient.
In the present study, perioperative mortality was significantly increased by the presence of heart failure symptoms as well as previous CABG surgery, and hospital length of stay was increased by advanced age, ICD implantation, and the presence and severity of heart failure symptoms. Notably, mortality was not influenced by age, sex, presence or severity of angina, hypertension, LVEDP, left main coronary artery disease, or severity of CHF. Although mortality increased progressively from 3.5% in patients without CHF to 5.7%, 8.1%, and 9.1% in patients with NYHA class I, II, and III CHF, respectively, a linear relationship between CHF class and mortality could not be established because patients with class IV CHF had a mortality of only 4.7%. Although this decrement in mortality in patients with the most advanced degrees of heart failure might be explained by proportionately greater improvements in myocardial function after revascularization, it is also likely due to the fact that patients with class IV CHF who undergo CABG are highly selected, with optimal revascularization targets and minimal comorbid conditions. 22 Finally, the low overall operative mortality encountered in our cohort was especially notable in light of the fact that all patients had an abnormal preoperative signalaveraged ECG, which has been shown to predict poor recovery of myocardial function (and poor prognosis) after CABG. 23 A potential limitation of the present study was the sample size of 900 patients that constituted the CABG Patch Trial, which is relatively small compared with other studies of risk factors among unselected CABG patients. With the low mortality rates encountered in our cohort, power to detect differences in mortality according to certain variables may have been limited. Nonetheless, compared with other published studies focusing on patients with ejection fractions Ͻ0.40, our analysis examined approximately twice the number of patients as the next largest study. 7 In conclusion, the present study demonstrates that despite traditional concerns about operative risks in patients with ventricular dysfunction, patients without heart failure symptoms may undergo CABG with low mortality despite low ejection fraction, high LVEDP, advanced age, an abnormal signal-averaged ECG, or comorbid conditions such as diabetes, hypertension, or chronic obstructive pulmonary disease. Furthermore, although the presence of clinical heart failure symptoms confers a Ͼ2-fold increase in the risk of death, patients with low ejection fraction and advanced heart failure may still expect a perioperative mortality rate of Ͻ10%. This increased mortality risk may not be prohibitively high in patients who stand to benefit significantly from surgical revascularization but certainly underscores the importance of proper selection of patients with surgically correctable ischemia. Finally, length of hospital stay, an increasingly important economic outcome variable, is significantly increased by advanced age, a history of stroke, and the presence and severity of clinical heart failure. Data do not include patients who died perioperatively. Data were missing for the following comparisons: heart failure (nϭ847), angina (nϭ793), reoperation (nϭ849), COPD (nϭ845), smoking (nϭ849), LVEDP (nϭ679), and left main disease (nϭ789). Data were analyzed by univariate linear regression (see Methods). 
